Overview of Dr. Masias
I am a board certified hematologist and medical oncologist. I completed my training at the Ohio State University - James Comprehensive Cancer Center, where I also completed a Masters in Public Health with an emphasis in clinical and translational research. I devote my clinical practice to the field of classical hematology, and have a research interest in thrombotic microangiopathies and platelet disorders.
Office
8900 N Kendall Dr
Miami, FL 33176Fax+1 305-279-7778
Education & Training
- The Ohio State University Master of Public Health, Clinical and Translational Research , 2017 - 2019
- Ohio State University HospitalFellowship, Hematology and Medical Oncology, 2015 - 2018
- Icahn School of Medicine at Mount Sinai/Beth IsraelResidency, Internal Medicine, 2011 - 2014
- Cayetano Heredia UniversityClass of 2008
Certifications & Licensure
- FL State Medical License 2019 - 2026
- OH State Medical License 2015 - 2021
- NY State Medical License 2014 - 2016
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Clinical Research Training Insitute American Society of Hematology, 2019
- Outstanding Clinical Care Award The Ohio State University, hematology and Oncology fellowship, 2018
Publications & Presentations
PubMed
- Relapse Free Survival Progressive Shortens in a Subset of Black patients with Immune TTP Treated in the Rituximab Era.Ayotola A Fatola, Michael D Evans, Jenna Brown, Elizabeth Davis, Andrew David Johnson
Blood Advances. 2024-12-03 - When you think you should transfuse…don't!Richard R Gammon, Harold Alvarez, Camila Masias, Nancy Benitez, Claribel Resto
Laboratory Medicine. 2024-09-04 - A machine learning approach to predict mortality due to immune-mediated thrombotic thrombocytopenic purpura.Mouhamed Yazan Abou-Ismail, Chong Zhang, Angela P Presson, Shruti Chaturvedi, Ana G Antun
Research and Practice in Thrombosis and Haemostasis. 2024-03-01
Journal Articles
- The Role of ADAMTS13 Testing in the Diagnosis and Management of Thrombotic Microangiopathies and ThrombosisSpero R Cataland, Camila Masias, Blood
Authored Content
- ASH 22 Presentation Preview: Most/All Patients With Acquired (Immune) Thrombotic Thrombocytopenic Purpura Receive CaplacizumabDecember 2022
Professional Memberships
- Member
- Member
Other Languages
- Spanish
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: